10-Q quarterly report · filed Nov 9, 2026

NOVANTA INC (NOVT) Q4 2026 10-Q Quarterly Report

Short answer

NOVANTA INC (NOVT) filed its Q4 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Oct 2, 2026. Quarterly revenue was $305M (up 23.1% year over year) with net income of $2M.

Q4 2026 key financials · XBRL

Revenue
$305M
+23.1% YoY · +14.7% QoQ
Net income
$2M
−81.1% YoY · −83.9% QoQ
Operating margin
4.6%
Gross margin
44.5%
EPS (diluted)
$0.04
−86.7% YoY · −87.1% QoQ

Source: XBRL data from the NOVANTA INC (NOVT) Q4 2026 10-Q on SEC EDGAR. USD.

NOVANTA INC Q4 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $305.0M, up $57.2M or 23.1% YoY, including $32.9M from the 2026 acquisition
  • Total gross margin 44.5% vs 44.8% YoY, operating margin 4.6% vs 8.8% YoY
  • Best segment Automation Enabling Technologies: revenue $145.4M, up 16.0%, operating margin 28.1% vs 21.8%
  • Worst segment Medical Solutions margin: operating margin 6.0% vs 13.0%, gross margin 39.9% vs 43.0%
  • Cash $149.2M vs $380.9M, operating cash flow $155.9M, acquisition investment $1,200.6M, 2026 capex outlook $30M to $40M

Risk Factors

  • Newly added geopolitical risk: February 2026 U.S.-Israel-Iran conflict increased energy, freight and commodity costs
  • Most material acquisition risk: Riverpoint Medical purchase for $1,200.6 million heightened integration and impairment exposure
  • Regulatory risk: Chinese export-license restrictions delayed rare-earth material shipments and customer order fulfillment
  • Operational risk: Limited or single-source components could cause missed shipments and permanent customer-order losses
  • Financial risk: Total debt increased to $838.6 million as of October 2, 2026, raising variable-rate exposure

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other NOVANTA INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.